NICE's New Office For Market Access: An Unlikely Game-Changer
This article was originally published in Scrip
The official launch of the National Institute for health and Clinical Excellence's Office for Market Access (OMA), announced Sept. 13 at NICE's annual meeting in Liverpool, UK, offers companies the possibility of smoother interactions with the health technology assessor, but doesn't radically change the way drugs will assessed or decisions made on whether the products should be used in the National Health Service.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Two European pharmaceutical companies, UCB and Merck KGaA, are exploring artificial intelligence in different ways, the first for drug discovery and the second on a fundamental level.
Italy’s Italfarmaco expects top-line data from its pivotal Phase III study of givinostat in Duchenne muscular dystrophy in the middle of next year, as the HDAC inhibitor continues to accrue data from the extension of its Phase II study.